Sunday Prep 9/12 - $ABUS Higher The Better! The higher the better on this name, but will be stalking it for lower highs and an area to get short with defined risk.
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−0.41EUR
−66.00 MEUR
16.44 MEUR
146.65 M
About Arbutus Biopharma Corporation
Sector
CEO
Michael J. McElhaugh
Headquarters
Warminster
Website
Employees (FY)
73
Founded
2005
FIGI
BBG000R8Z1H3
Arbutus Biopharma Corp. is a clinical-stage biopharmaceutical company, which engages in developing novel therapeutics that target specific viral diseases. It focuses on the Hepatitis B virus, SARS-CoV-2, and other coronaviruses. The company was founded on October 6, 2005 and is headquartered in Warminster, PA.
An aggregate view of professional's ratings.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of I9DN is 2.79 EUR — it has decreased by 2.04% in the past 24 hours. Watch ARBUTUS BIOPHARMA CORP stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on GETTEX exchange ARBUTUS BIOPHARMA CORP stocks are traded under the ticker I9DN.
I9DN stock has risen by 2.12% compared to the previous week, the month change is a 7.92% fall, over the last year ARBUTUS BIOPHARMA CORP has showed a 33.49% increase.
We've gathered analysts' opinions on ARBUTUS BIOPHARMA CORP future price: according to them, I9DN price has a max estimate of 4.62 EUR and a min estimate of 3.70 EUR. Watch I9DN chart and read a more detailed ARBUTUS BIOPHARMA CORP stock forecast: see what analysts think of ARBUTUS BIOPHARMA CORP and suggest that you do with its stocks.
I9DN reached its all-time high on Dec 1, 2021 with the price of 5.73 EUR, and its all-time low was 1.61 EUR and was reached on Oct 23, 2023. View more price dynamics on I9DN chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
I9DN stock is 2.08% volatile and has beta coefficient of 0.78. Track ARBUTUS BIOPHARMA CORP stock price on the chart and check out the list of the most volatile stocks — is ARBUTUS BIOPHARMA CORP there?
Today ARBUTUS BIOPHARMA CORP has the market capitalization of 537.31 M, it has increased by 2.07% over the last week.
Yes, you can track ARBUTUS BIOPHARMA CORP financials in yearly and quarterly reports right on TradingView.
ARBUTUS BIOPHARMA CORP is going to release the next earnings report on Aug 1, 2024. Keep track of upcoming events with our Earnings Calendar.
I9DN earnings for the last quarter are −0.09 EUR per share, whereas the estimation was −0.10 EUR resulting in a 9.09% surprise. The estimated earnings for the next quarter are −0.09 EUR per share. See more details about ARBUTUS BIOPHARMA CORP earnings.
ARBUTUS BIOPHARMA CORP revenue for the last quarter amounts to 1.42 M EUR, despite the estimated figure of 2.52 M EUR. In the next quarter, revenue is expected to reach 1.65 M EUR.
I9DN net income for the last quarter is −16.57 M EUR, while the quarter before that showed −17.50 M EUR of net income which accounts for 5.32% change. Track more ARBUTUS BIOPHARMA CORP financial stats to get the full picture.
No, I9DN doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Jun 26, 2024, the company has 73.00 employees. See our rating of the largest employees — is ARBUTUS BIOPHARMA CORP on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. ARBUTUS BIOPHARMA CORP EBITDA is −72.89 M EUR, and current EBITDA margin is −422.41%. See more stats in ARBUTUS BIOPHARMA CORP financial statements.
Like other stocks, I9DN shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade ARBUTUS BIOPHARMA CORP stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So ARBUTUS BIOPHARMA CORP technincal analysis shows the sell today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating ARBUTUS BIOPHARMA CORP stock shows the buy signal. See more of ARBUTUS BIOPHARMA CORP technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.